tislelizumab
Showing 1 - 25 of 169
Unresectable Hepatocellular Carcinoma Trial in Nanchang (D-TACE, HAIC, Lenvatinib)
Recruiting
- Unresectable Hepatocellular Carcinoma
- D-TACE
- +3 more
-
Nanchang, Jiangxi, ChinaThe Second Affiliated Hospital of Nanchang University
Oct 14, 2022
Resectable Hepatocellular Carcinoma Trial (Tislelizumab, Tislelizumab, Lenvatinib)
Not yet recruiting
- Resectable Hepatocellular Carcinoma
- Tislelizumab
- Tislelizumab, Lenvatinib
- (no location specified)
Mar 29, 2023
Immunotherapy Trial (Tislelizumab, Capecitabine, oxaliplatin)
Not yet recruiting
- Immunotherapy
- Tislelizumab
- +4 more
- (no location specified)
Jul 28, 2022
Recurrent Hepatocellular Carcinoma Trial in Guangzhou (Tislelizumab, Tislelizumab combined with Levatinib)
Recruiting
- Recurrent Hepatocellular Carcinoma
- Tislelizumab
- Tislelizumab combined with Levatinib
-
Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Sun Yat-sen University
Mar 31, 2022
Esophageal Cancer Trial (Tislelizumab, Radiation, Paclitaxel)
Not yet recruiting
- Esophageal Cancer
- Tislelizumab
- +3 more
- (no location specified)
Nov 18, 2022
Gastric Cancer Trial (Tislelizumab, 5Fu, Paclitaxel injection)
Not yet recruiting
- Gastric Cancer
- Tislelizumab
- +2 more
- (no location specified)
Feb 21, 2023
MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin Trial (Tislelizumab)
Not yet recruiting
- MSI-H Colorectal Cancer
- +3 more
- Tislelizumab
- (no location specified)
Apr 23, 2023
Non Small Cell Lung Cancer Trial (Tislelizumab, Ociperlimab, LBL-007)
Not yet recruiting
- Non Small Cell Lung Cancer
- Tislelizumab
- +2 more
- (no location specified)
Jan 30, 2023
Pancreatic Tumors Trial (Tislelizumab)
Not yet recruiting
- Pancreatic Neoplasms
- Tislelizumab
- (no location specified)
Dec 26, 2022
Melanoma Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)
Recruiting
- Melanoma
- Tislelizumab
- +2 more
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Nov 8, 2022
Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation Trial in Nanjing (Tislelizumab, Paclitaxel, Carboplatin)
Recruiting
- Esophageal Squamous Cell Carcinoma
- +2 more
- Tislelizumab
- +3 more
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Institute & Hospital
May 24, 2022
Nasopharyngeal Carcinoma Trial in Beijing (Tislelizumab)
Recruiting
- Nasopharyngeal Carcinoma
- Tislelizumab
-
Beijing, Beijing, ChinaNational Cancer Center /National Clinical Research Center for Ca
Jul 4, 2022
NSCLC Trial in Zhengzhou (Tislelizumab)
Active, not recruiting
- NSCLC
- Tislelizumab
-
Zhengzhou, Hennan, ChinaThe First Affiliated Hospital of Zhengzhou University
Oct 31, 2022
Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)
Not yet recruiting
- Metastatic Cervical Cancer
- Tislelizumab
- Sitravatinib
- (no location specified)
Jan 31, 2023
Stage III NSCLC Trial in Guangzhou (Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy)
Recruiting
- Stage III Non-small Cell Lung Cancer
- Neoadjuvant chemo-immunotherapy
- +5 more
-
Guangzhou, ChinaSun Yat-sen University
Jul 19, 2022
Biliary Tract Carcinoma Trial in Beijing (Gemcitabine, S1, Tislelizumab)
Not yet recruiting
- Biliary Tract Carcinoma
- Gemcitabine
- +2 more
-
Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical Colle
Apr 10, 2023
Colorectal Cancer Trial (Tislelizumab, Irinotecan Hydrochloride, cetuximab)
Not yet recruiting
- Colorectal Cancer
- Tislelizumab
- +3 more
- (no location specified)
Mar 23, 2023
Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)
Recruiting
- Urothelial Carcinoma
- AZD4547
- Tislelizumab
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 8, 2023
Pancreatic Cancer Trial in Baltimore (Tislelizumab, SX-682)
Not yet recruiting
- Pancreatic Cancer
- Tislelizumab
- SX-682
-
Baltimore, MarylandJohns Hopkins SKCCC
Jan 23, 2023
Immunotherapy Esophagus Cancer Trial (Tislelizumab, Albumin paclitaxel, Nedaplatin)
Not yet recruiting
- Immunotherapy Esophagus Cancer
- Tislelizumab
- +3 more
- (no location specified)
Aug 24, 2022
Muscle Invasive Bladder Cancer, Urothelial Carcinoma Trial in Tianjin (Tislelizumab, Nab paclitaxel)
Active, not recruiting
- Muscle Invasive Bladder Cancer
- Urothelial Carcinoma
- Tislelizumab
- Nab paclitaxel
-
Tianjin, Tianjin, ChinaTianjin Medical University Second Hospital
Nov 23, 2022
Head Neck Cancer Trial in Chengdu, Tianjin (Tislelizumab, Pulse radiation)
Recruiting
- Head and Neck Cancer
- Tislelizumab
- Pulse radiation
-
Chengdu, Sichuan, China
- +1 more
Oct 25, 2022
Gastric Cancer, Gastroesophageal-junction Cancer Trial in Wuhan, Nanjing, Taiyuan (Tislelizumab, S-1, Oxaliplatin)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Tislelizumab
- +4 more
-
Wuhan, Hubei, China
- +2 more
Jan 16, 2023